Decreased level of soluble receptors of advanced glycated end products (sRAGE) and glycine82serine (G82S) polymorphism in Egyptian patients with RA

Egyptian Rheumatologist

Volumn 33, Issue 1, 2011, Pages 53-60

  Mokbel, A ^a   Rashid, L ^a   Al Harizy, R ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

DAS28 ESR; Glycine82serine gene polymorphism; Rheumatoid arthritis; SRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; GLYCINE; SERINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME IMMUNOASSAY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MALE; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SJOEGREN SYNDROME;

EID: 84880396043     PISSN: 11101164     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejr.2010.12.002     Document Type: Article

References (35)

1. Carroll L., Hannawi S., Marwick T., Thomas R. Rheumatoid arthritis: links with cardiovascular disease and the receptor for advanced glycation end products. Wien Med Wochenschr 2006, 156:42-52.
2. Sunahori K., Yamamura M., Yamana J., Takasugi K., Kawashima M., Makino H. Increased expression of receptor for advanced glycation end products by synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2006, 54:97-104.
3. Yan S.F., Ramasamy R., Schmidt A.M. Mechanisms of disease advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008, 4(5):285-293.
4. Srikrishna G., Huttunen H.J., Johansson L., Weigle B., Yamaguchi Y., Rauvala H., et al. N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J Neurochem 2002, 80:998-1008.
5. Hudson B.I., Kalea A.Z., Arriero M., Harja E., Boulanger E., D'Agati V., et al. Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 2008, 283:34457-34468.
6. Hudson B.I., Harja E., Moser B., Schmidt A.N. Advanced glycation endproducts (sRAGE) and coronary artery disease: is RAGE the next C-reactive protein?. Arterioscler Thromb Vasc Biol 2005, 25(5):879.
7. Bengmark S., Hajdú N. Endproducts and receptor of advanced glycation and lipoxidation (AGE, ALE, RAGE) and chronic diseases - a food perspective. Orv Hetil 2008, 149(17):771-778.
8. Drinda S., Franke S., Ruster M., Petrow P., Pullig O., Stein G., et al. Identification of the receptor for advanced glycation end products in synovial tissue of patients with rheumatoid arthritis. Rheumatol Int 2005, 25(6):411-413.
9. Hou F.F., Jiang J.P., Guo J.Q., Wang G.B., Zhang X., Stern D.M., et al. Receptor for advanced glycation end products on human synovial fibroblasts: role in the pathogenesis of dialysis-related amyloidosis. J Am Soc Nephrol 2002, 13:1296-1306.
10. Sparvero L., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J., et al. RAGE (receptor for advanced glycation endproducts), RAGELigands, and their role in cancer and inflammation. J Trans Med 2009, 7:17.
11. Chen Y., Yan W., Geczy C., Brown M., Thomas R. Serum levels of soluble receptor for advanced glycation end-products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R39.
12. Bucciarelli L.G., Wendt T., Rong L., Lalla E., Hofmann M.A., Goova M.T., et al. RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 2002, 59:1117-1128.
13. Taniguchi N., Kawahara K., Yone K., Hashiguchi T., Yamakuchi M., Goto M., et al. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 2003, 48:971-981.
14. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003, 370:1097-1109.
15. Falcone C., Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006, 13(17):1971-1978.
16. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M.P., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 2005, 23:1725-1729.
17. Pullerits R., Bokarewa M., Dahlberg L., Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res Ther 2005, 7(4):R817-R824.
18. Schmidt A.M., Yan S.D., Yan S.F., Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 2001, 108:949-955.
19. Hofmann M.A., Drury S., Hudson B.I., Gleason M.R., Qu W., Lu Y., et al. RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 2002, 3:123-135.
20. Prevost G., Fajardy I., Fontaine P., Danze P.M., Besmond C. Human RAGE GLY82SER dimorphism and HLA class II DRB1-DQA1-DQB1 haplotypes in type 1 diabetes. Eur J Immunogenet 1999, 26:343-348.
21. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
22. van Gestel A.M., Haasgma C.J., van Reil P.L.M.C. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998, 41:1845-1850.
23. Price C.P., Trull A.K., Berry D., Garman E.G. Development and validation of a particles enhanced turbidimetric immunoassay for C-reactive protein. J Immunol Methods 1987, 99:205-211.
24. Huttunen H.J., Kuja-Panula J., Sorci G., Agneletti A.L., Donato R., Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation. J Biol Chem 2000, 22:40096-40105.
25. Hudson B.I., Stickland M.H., Grant P.J. Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene. Diabetes 1998, 47:1155-1157.
26. Moser B., Hudson B.I., Schmidt A.M. Soluble RAGE: a hot new biomarker for the hot joint?. Arthritis Res Ther 2005, 7(4):142-144.
27. Andersson U., Erlandsson-Harris H. HMGB1 is a potent trigger of arthritis. J Intern Med 2004, 255:344-350.
28. Ulloa L., Batliwalla F.M., Andersson U., Gregersen P.K., Tracey K.J. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum 2003, 48:876-881.
29. Foell D., Kane D., Bresnihan B., Vogl T., Nacken W., Sorg C., et al. Expression of the pro-inflammatory protein S100A12 (EN-RAGE) in rheumatoid and psoriatic arthritis. Rheumatology 2003, 42:1383-1389.
30. Sunahori K., Yamamura M., Yamana J., Takasugi K., Kawashima M., Yamamoto H., et al. The S100A8/A9 heterodimer amplifies proinflammatory cytokine production by macrophages via activation of nuclear factor-kappaB, p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006, 8:R69.
31. Vytášek R., Šedová L., Vilím V. Increased concentration of two different advanced glycation endproducts detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. BMC Musculoskelet Disord 2010, 11:83.
32. Renard C., Chappey O., Wautier M.P., Nagashima M., Lundh E., Morser J., et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol 1997, 52:54-62.
33. Katz J., Stavropoulos F., Bhattacharyya I., Stewart C., Perez F.M., Caudle R.M. Receptor of advanced glycation end product (RAGE) expression in the minor salivary glands of patients with Sjogren's syndrome: a preliminary study. Scand J Rheumatol 2004, 33(3):174-178.
34. Carroll L., Frazer I.H., Turner M., Marwick T.H., Thomas R. Receptor for advanced glycation end products Glycine 82 Serine polymorphism and risk of cardiovascular events in rheumatoid arthritis. Arthritis Res Ther 2007, 9(2):R39.
35. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation endproducts and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 2005, 25:1032-1037.